Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses
- 12 February 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (530)
- https://doi.org/10.1126/scitranslmed.aax6337
Abstract
Solid tumors elicit a detectable immune response including the infiltration of tumor-associated macrophages (TAMs). Unfortunately, this immune response is co-opted into contributing toward tumor growth instead of preventing its progression. We seek to reestablish an antitumor immune response by selectively targeting surface receptors and endogenous signaling processes of the macrophage subtypes driving cancer progression. RP-182 is a synthetic 10-mer amphipathic analog of host defense peptides that selectively induces a conformational switch of the mannose receptor CD206 expressed on TAMs displaying an M2-like phenotype. RP-182-mediated activation of this receptor in human and murine M2-like macrophages elicits a program of endocytosis, phagosome-lysosome formation, and autophagy and reprograms M2-like TAMs to an antitumor M1-like phenotype. In syngeneic and autochthonous murine cancer models, RP-182 suppressed tumor growth, extended survival, and was an effective combination partner with chemo- or immune checkpoint therapy. Antitumor activity of RP-182 was also observed in CD206(high )patient-derived xenotransplantation models. Mechanistically, via selective reduction of immunosuppressive M2-like TAMs, RP-182 improved adaptive and innate antitumor immune responses, including increased cancer cell phagocytosis by reprogrammed TAMs.Funding Information
- National Institutes of Health (ZIA BC 011267)
- National Institutes of Health (U54 CA118623 (NIH/ NCI))
- U.S. Department of Defense (PC120913)
- U.S. Department of Defense (W81XWH-10-1-0543)
- National Cancer Institute (HHSN26120080001E)
- National Center for Advancing Translational Sciences (ZIA TR000302-02)
- National Institute on Minority Health and Health Disparities (U54-MD007585-26 NIH/NIMHD)
This publication has 46 references indexed in Scilit:
- Targeting macrophages: therapeutic approaches in cancerNature Reviews Drug Discovery, 2018
- Diverse Functions of Macrophages in Different Tumor MicroenvironmentsCancer Research, 2018
- Cancer immunotherapy using checkpoint blockadeScience, 2018
- Roles for Innate Immunity in Combination ImmunotherapiesCancer Research, 2017
- Tumour-associated macrophages as treatment targets in oncologyNature Reviews Clinical Oncology, 2017
- Entering the mainstream of cancer treatmentNature Reviews Clinical Oncology, 2014
- Innate and adaptive immune cells in the tumor microenvironmentNature Immunology, 2013
- Accessories to the Crime: Functions of Cells Recruited to the Tumor MicroenvironmentCancer Cell, 2012
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- An anti-infective peptide that selectively modulates the innate immune responseNature Biotechnology, 2007